These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27677698)

  • 1. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection.
    Carmona I; Cordero P; Ampuero J; Rojas A; Romero-Gómez M
    Clin Microbiol Infect; 2016 Oct; 22(10):839-845. PubMed ID: 27677698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
    Roche B; Coilly A; Duclos-Vallee JC; Samuel D
    Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
    Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
    Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
    Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversion of disease manifestations after HCV eradication.
    van der Meer AJ; Berenguer M
    J Hepatol; 2016 Oct; 65(1 Suppl):S95-S108. PubMed ID: 27641991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?
    D'Ambrosio R; Colombo M
    Liver Int; 2016 Jun; 36(6):783-90. PubMed ID: 26936383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
    Celli R; Saffo S; Kamili S; Wiese N; Hayden T; Taddei T; Jain D
    Arch Pathol Lab Med; 2021 Apr; 145(4):419-427. PubMed ID: 32810870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.
    Jacobson IM; Lim JK; Fried MW
    Gastroenterology; 2017 May; 152(6):1578-1587. PubMed ID: 28344022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.
    Haseltine EL; Penney MS; George S; Kieffer TL
    J Viral Hepat; 2015 Sep; 22(9):701-7. PubMed ID: 25582683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
    D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
    J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
    Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis.
    van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.
    Mauro E; Crespo G; Montironi C; Londoño MC; Hernández-Gea V; Ruiz P; Sastre L; Lombardo J; Mariño Z; Díaz A; Colmenero J; Rimola A; Garcia-Pagán JC; Brunet M; Forns X; Navasa M
    Hepatology; 2018 May; 67(5):1683-1694. PubMed ID: 28960366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.
    Knop V; Hoppe D; Welzel T; Vermehren J; Herrmann E; Vermehren A; Friedrich-Rust M; Sarrazin C; Zeuzem S; Welker MW
    J Viral Hepat; 2016 Dec; 23(12):994-1002. PubMed ID: 27500382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up of patients with chronic hepatitis C and a sustained viral response.
    Serfaty L
    Liver Int; 2016 Jan; 36 Suppl 1():67-71. PubMed ID: 26725900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
    Poynard T; Moussalli J; Munteanu M; Thabut D; Lebray P; Rudler M; Ngo Y; Thibault V; Mkada H; Charlotte F; Bismut FI; Deckmyn O; Benhamou Y; Valantin MA; Ratziu V; Katlama C;
    J Hepatol; 2013 Oct; 59(4):675-83. PubMed ID: 23712051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
    Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
    Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
    van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.